ProCE Banner Activity

My Thoughts on New Therapeutic Strategies for Graft Versus Host Disease From TCT 2020

Clinical Thought
Review this expert perspective on key clinical findings in GVHD reported at the TCT meeting.

Released: March 16, 2020

Expiration: March 15, 2021

No longer available for credit.

Share

Faculty

Corey Cutler

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Incyte

Pharmacyclics Inc

Faculty Disclosure

Primary Author

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Corey S. Cutler, MD, MPH, FRCPC, has disclosed that he has received consulting fees from Elsalys, Fresenius, Genentech, Generon, Incyte, Jazz, Kabi, Kadmon, Medsenic, Omeros, and Pharmacyclics.